A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

Clinical trial NCT05594043 · COMPLETED

Trial details

NCT number: NCT05594043
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced or Metastatic Solid Tumors

Start date: 2022-12-21
Primary completion: 2025-05-21
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.